secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2023-04-17T23:59:59+00:00
Accession:  0001493152-23-012566
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaCell presents positive Bria-IMT data at AACR; 15/18 alive, immune activation in anergic patients
--------------------------------------------------------------------------------

- 15 of 18 patients enrolled since 2021 remain alive; survival compares favorably to 6.7-9.8 months in similar studies.
- PFS benefit: most patients had PFS similar or higher than prior therapy, suggesting better tolerability and clinical effectiveness.
- Immune activation in 70% of anergic patients (weak immune systems) and 89% of non-anergic after Bria-IMT combo.
- 8 of 17 HR+ patients (large segment) experienced PFS benefit; no immunotherapies shown to work in HR+ breast cancer.
- Next-gen Bria-OTS2.0 significantly more effective than Bria-OTS in activating naïve T-cells; planned for Phase I/IIa.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315223012566/0001493152-23-012566-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315223012566/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-012566

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer